Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Western blot analysis of ERK phosphorylation in HUVECs stimulated for 10 min with AGR2 coupled with or without FGF/VEGF. The concentration of AGR2 is 500 ng/ml. The concentration of VEGF is 5 ng/ml. PD173074: FGFR inhibitor; Axitinib: VEGFR inhibitor (2 nm); BEV: VEGF antibody bevacizumab (5 μg/ml). Quantification of ERK activity was performed by normalizing phosphorylated ERK to β-actin, untreated control (lane 1) was set to 1. All data represent four independent biological replicates and shown as means±s.d. Asterisks indicate significant differences (*, Pless than or equal to0.05; **, Pless than or equal to0.01).

    Oncogene, 2017, 36(36):5098-5109. Axitinib purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

  • Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHkeG5KSzVyPUCuNFAxODVzMzFOwG0> M3f1SHNCVkeHUh?=
NCI-H1703 M4q5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMECwPVAzKM7:TR?= MmH2V2FPT0WU
KASUMI-1 NXjQSmFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHs[mhKSzVyPUCuNFA3QDJizszN NUS1XYJmW0GQR1XS
CGTH-W-1 NWTmSmdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f3emlEPTB;MD6wNFczOiEQvF2= MXzTRW5ITVJ?
A204 NWLYfohIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki5TWM2OD1yLkCwPVkzKM7:TR?= NWnLWJJpW0GQR1XS
HOP-62 NED1W4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX6WWxbUUN3ME2wMlExQDN4IN88US=> MVjTRW5ITVJ?
H-EMC-SS M3jocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMUGwNFUh|ryP Mn25V2FPT0WU
KU812 NUjkOnRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXRRmRIUUN3ME2wMlE3PTd5IN88US=> NGPVbXFUSU6JRWK=
EM-2 NWjoR4RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMU[4NVYh|ryP NHj3XJNUSU6JRWK=
LAMA-84 M4HNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMUe2OlUh|ryP MmDIV2FPT0WU
JAR MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX0TWM2OD1yLkKzPVg6KM7:TR?= MnXIV2FPT0WU
G-361 MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmOxTWM2OD1yLkOyN|I2KM7:TR?= MYfTRW5ITVJ?
KG-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D0ZWlEPTB;MD6zO|Y1OiEQvF2= MmrkV2FPT0WU
BV-173 NWL0eVZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwM{mzNkDPxE1? MorUV2FPT0WU
K5 M{nTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwNEKxNlch|ryP MYXTRW5ITVJ?
MEG-01 NFrBN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvKTWM2OD1yLkSyN|YyKM7:TR?= MXrTRW5ITVJ?
MFM-223 NUfDb41GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPnTWM2OD1yLkS0O|c3KM7:TR?= NWDsdXJjW0GQR1XS
BE-13 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnHPHBKSzVyPUCuOVExODhizszN M4e1[HNCVkeHUh?=
NEC8 NYXuRnlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuzSlZKSzVyPUCuO|IyOTNizszN MXjTRW5ITVJ?
SW756 NH;BN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwOUm4OFYh|ryP MnTxV2FPT0WU
A2780 MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m4eWlEPTB;MT6wNVE1PiEQvF2= M3nhUnNCVkeHUh?=
NB14 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H3T2lEPTB;MT6wNVgxOSEQvF2= M{np[3NCVkeHUh?=
H4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfJXHZKSzVyPUGuNFY1OjJizszN MonhV2FPT0WU
SK-OV-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS4PWNkUUN3ME2xMlA3PjN|IN88US=> NYL5U4Z[W0GQR1XS
AN3-CA Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2e5XmlEPTB;MT6wPFM5QSEQvF2= M{\NUXNCVkeHUh?=
A427 M13IWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETv[|RKSzVyPUGuNVA{QDFizszN NUfCNGw1W0GQR1XS
ES7 M2f4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7vTWM2OD1zLkGxN|M1KM7:TR?= MV3TRW5ITVJ?
AGS MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n6emlEPTB;MT6xNVM6PSEQvF2= NUnkelczW0GQR1XS
G-402 NFXWd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwMUS2PVQh|ryP MYHTRW5ITVJ?
ES5 NYXF[4FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHHTWM2OD1zLkG3NlQ5KM7:TR?= NI\neWNUSU6JRWK=
DEL NUHSbng3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLLbFhKSzVyPUGuNlU1PTdizszN M1vEXnNCVkeHUh?=
NB10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPPTWM2OD1zLkOyOVU4KM7:TR?= MYTTRW5ITVJ?
NCI-H1581 NFzEfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwM{mwOFIh|ryP MWjTRW5ITVJ?
D-566MG M{nwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzGSYJUUUN3ME2xMlQxPjh|IN88US=> NFPQbItUSU6JRWK=
LXF-289 MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rXWGlEPTB;MT60N|k6PiEQvF2= MoTjV2FPT0WU
BT-549 Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH4[4tKSzVyPUGuOVY6ODlizszN MUXTRW5ITVJ?
NKM-1 M2TNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTLUG5mUUN3ME2xMlYxPTV4IN88US=> NX24eZpFW0GQR1XS
SW780 M33nUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwNkWxOVgh|ryP M4\zUHNCVkeHUh?=
NCI-H292 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr5cY1KSzVyPUGuOlY{QDNizszN NIfY[nVUSU6JRWK=
HMV-II MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDnT4pKSzVyPUGuO|A1QDhizszN NHTtdmJUSU6JRWK=
ALL-PO MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLrUZZWUUN3ME2xMlgxODF3IN88US=> NXvKOJN6W0GQR1XS
UACC-257 Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\6TWM2OD1zLkiyNVY{KM7:TR?= NILkOIdUSU6JRWK=
PA-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7vbW5KSzVyPUGuPFI4OjVizszN NXLtNXZOW0GQR1XS
HD-MY-Z MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPLU45KSzVyPUGuPFYzQDFizszN NEXoUZdUSU6JRWK=
HSC-4 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD4TWM2OD1zLkmzPFM6KM7:TR?= NYDGOFZxW0GQR1XS
GCT Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJwMEC5NVYh|ryP NFPsSHlUSU6JRWK=
RT-112 NHXhcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJwMUO0NlQh|ryP M1nZ[XNCVkeHUh?=
A172 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz0TWM2OD1{LkGzOlA3KM7:TR?= NGexWZhUSU6JRWK=
HCE-T MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G2T2lEPTB;Mj6yNFU6QCEQvF2= Ml3oV2FPT0WU
YH-13 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfhN|hKSzVyPUKuNlE3PzFizszN MXXTRW5ITVJ?
DK-MG MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJwMkO4N|Qh|ryP M2PtRnNCVkeHUh?=
ACN M1zkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJwMkO4O|Uh|ryP NGP0ZWpUSU6JRWK=
VA-ES-BJ NIf0e3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LB[2lEPTB;Mj6yOFk2PyEQvF2= NUDLZ|RMW0GQR1XS
L-363 NGDiOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzKO3FKSzVyPUKuNlgxPjFizszN M1PjXnNCVkeHUh?=
HuH-7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLoTWM2OD1{LkSyNVY2KM7:TR?= Ml;JV2FPT0WU
A4-Fuk NEDzNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XVV2lEPTB;Mj60O|E3QCEQvF2= MVjTRW5ITVJ?
T-24 NXTmRVhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrXTWM2OD1{LkS4NFM4KM7:TR?= M3Xy[HNCVkeHUh?=
GOTO NWXUdVI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H1XGlEPTB;Mj61N|AyOyEQvF2= M4\KXnNCVkeHUh?=
MV-4-11 NF7pWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTyTWM2OD1{LkW5NVY6KM7:TR?= M{WzTXNCVkeHUh?=
DMS-114 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[5TWM2OD1{Lk[2N|Q2KM7:TR?= M2rVXXNCVkeHUh?=
MHH-NB-11 NUHsUYFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrmbpJxUUN3ME2yMlcxOjl7IN88US=> M125UXNCVkeHUh?=
CHP-212 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rUZWlEPTB;Mj64NlA6OSEQvF2= NFGzUnhUSU6JRWK=
DMS-273 M3fBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXreW9lUUN3ME2yMlkxOjB5IN88US=> MYjTRW5ITVJ?
SF295 M4nK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSwb|VpUUN3ME2zMlAzPTl5IN88US=> NXPlR5hWW0GQR1XS
NCI-H1563 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILNcmZKSzVyPUOuNVUxODVizszN M33iVXNCVkeHUh?=
NCI-H446 M{TjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX3SnVKSzVyPUOuNlI5ODVizszN NILDWG5USU6JRWK=
HCC1806 NF\LRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTNwMke2OVch|ryP M{DsR3NCVkeHUh?=
SF126 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\DTWM2OD1|LkOwNFE4KM7:TR?= M161WnNCVkeHUh?=
SW982 NVSwWHdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe1U29KSzVyPUOuN|M5PzVizszN M2P3R3NCVkeHUh?=
ES8 M1fEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1npWWlEPTB;Mz6zOFk6QSEQvF2= NGTQdpBUSU6JRWK=
SCC-4 NHjMdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfUTWM2OD1|LkWwN|k3KM7:TR?= NXnybVB2W0GQR1XS
RPMI-8226 M3Pp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTNwNkK2NVYh|ryP M{LrNHNCVkeHUh?=
EW-11 M3nERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1GzdGlEPTB;Mz62N|AzOiEQvF2= NV3lXoRrW0GQR1XS
COR-L105 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTNwNkOzN|Qh|ryP MmLrV2FPT0WU
ES1 NV\mU3hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNwOEOwPVQh|ryP NV\NXGVvW0GQR1XS
KMOE-2 M3TjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPVZog{UUN3ME2zMlkyQDB6IN88US=> M4P5UHNCVkeHUh?=
ABC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwOUO5NVEh|ryP MWPTRW5ITVJ?
NCI-H526 NHnrUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTNwOUmxNlYh|ryP NIjZXZdUSU6JRWK=
HCC1395 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwOUm0PFQh|ryP MmXHV2FPT0WU
DU-145 NIe1SZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fGUGlEPTB;ND6xNlgzPSEQvF2= NFvyN2hUSU6JRWK=
JEG-3 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPCTWM2OD12LkG1PVE3KM7:TR?= MlzhV2FPT0WU
HCC1187 NFPW[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO3VnFKSzVyPUSuNlE2QTdizszN MVHTRW5ITVJ?
LC-2-ad NFrZe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nLVGlEPTB;ND6yNlE4PyEQvF2= NFPLbWhUSU6JRWK=
ONS-76 M4KxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTRwMkSxPVIh|ryP M2XnWnNCVkeHUh?=
CAL-27 M{Wye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfldGpKSzVyPUSuNlQ{PDRizszN NEmxOGZUSU6JRWK=
8-MG-BA NGL0O4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPZdGtKSzVyPUSuNlY3PThizszN NVfCTlk3W0GQR1XS
HGC-27 NI\6OIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2zcIhKSzVyPUSuNlk3PiEQvF2= NVjVVoJQW0GQR1XS
Hs-578-T MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTXeZFKSzVyPUSuN|E1PjhizszN MUHTRW5ITVJ?
EW-1 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLXTWM2OD12LkWzNFE1KM7:TR?= Mlz3V2FPT0WU
SW1573 NITTdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXISm91UUN3ME20MlU2OTZ|IN88US=> NI\hbWRUSU6JRWK=
SNU-423 M2HlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3vcWMyUUN3ME20MlYxPzlizszN NEPhdIRUSU6JRWK=
HOS M4r4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[1TWM2OD12Lk[5O|ch|ryP MXXTRW5ITVJ?
LB1047-RCC NIPLdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfDUWxjUUN3ME20MlgyPDF6IN88US=> MnjTV2FPT0WU
ChaGo-K-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTRwOEmwOFgh|ryP NFfaXYtUSU6JRWK=
A3-KAW NUTDR|kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTRwOUezOVIh|ryP Mme0V2FPT0WU
CAS-1 MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\wWmlEPTB;ND65PVkxQCEQvF2= MlfZV2FPT0WU
NBsusSR NYDKNY9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX1R|F2UUN3ME21MlA{PTF2IN88US=> M2HGXXNCVkeHUh?=
KM12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX21cmhZUUN3ME21MlI6QDJ5IN88US=> NIjJS3lUSU6JRWK=
NCI-H1155 NELYXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvQZZBKSzVyPUWuN|gyQDVizszN MW\TRW5ITVJ?
EFM-19 NVy3NnNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLyUWdjUUN3ME21MlQyPzN5IN88US=> Ml7WV2FPT0WU
D-392MG NV3vd3FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TnUmlEPTB;NT61O|g1QSEQvF2= NIPRUHZUSU6JRWK=
JVM-3 M1\h[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTVwN{KzNlUh|ryP MlvwV2FPT0WU
EW-16 NG\IeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7PVW9KSzVyPUWuO|U2QDNizszN NXXudmg6W0GQR1XS
KARPAS-45 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjuTWM2OD13Lki0N|I2KM7:TR?= MUTTRW5ITVJ?
NCI-H28 M3znT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDkfZdKSzVyPUWuPFc6OThizszN NVO1TlJzW0GQR1XS
COLO-829 NHL3bHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T2PGlEPTB;NT65NVUxPCEQvF2= NWH3cYQ5W0GQR1XS
KM-H2 NGiweJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DtO2lEPTB;NT65NlM6PSEQvF2= MlLJV2FPT0WU
NCI-H82 MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jXO2lEPTB;NT65Nlc4OSEQvF2= M4LobnNCVkeHUh?=
OAW-42 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\uVG9KSzVyPUWuPVg5OjFizszN MWTTRW5ITVJ?
A704 M1v0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLxTWM2OD14LkGwOVc1KM7:TR?= MXjTRW5ITVJ?
NCI-H1048 M2LiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjJbWlKSzVyPU[uNVA2QTlizszN NFHiOIZUSU6JRWK=
LOXIMVI NFjFTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTZwMUGyOFgh|ryP MYTTRW5ITVJ?
MKN45 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonFTWM2OD14LkK2NFE3KM7:TR?= MV7TRW5ITVJ?
D-502MG MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTZwMki4OVch|ryP Mk[0V2FPT0WU
HUTU-80 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTEfVlUUUN3ME22MlQyPjh6IN88US=> NGrzZ|NUSU6JRWK=
S-117 M2WzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTZwNUCyOlch|ryP M3S1d3NCVkeHUh?=
HCC1569 NVvWVlZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3TTWM2OD14LkWzO|M4KM7:TR?= MV3TRW5ITVJ?
J-RT3-T3-5 NUPhbmdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OxcmlEPTB;Nj61OFU4OiEQvF2= MnLWV2FPT0WU
OC-314 M2qyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTZwOUGxOVkh|ryP MnzuV2FPT0WU
SNU-449 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPwTWM2OD15LkCxNFczKM7:TR?= MUDTRW5ITVJ?
NCI-H720 M2\kVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml62TWM2OD15LkG5N|Q2KM7:TR?= MXrTRW5ITVJ?
KP-N-YS MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTdwMkC3NkDPxE1? MkizV2FPT0WU
IGROV-1 Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jhe2lEPTB;Nz6zNlM5PiEQvF2= NHfLTpNUSU6JRWK=
SK-PN-DW MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTdwNEixOUDPxE1? M3;nZXNCVkeHUh?=
HCC1419 NIPQbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;XRXJKSzVyPUeuOVMh|ryP NX30TmxHW0GQR1XS
HAL-01 NFT3UWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTdwNkC2OFQh|ryP NY[w[GVkW0GQR1XS
HCC2998 NGTWPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXaPYVYUUN3ME23MlYxPzR|IN88US=> M4nG[nNCVkeHUh?=
SK-N-FI M1;nW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrWTWM2OD15Lk[zNFM{KM7:TR?= MkDYV2FPT0WU
GI-ME-N NGnTWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7xfFdKSzVyPUeuOlQ6OzRizszN NGrYNI5USU6JRWK=
SW1088 NVrwV|ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LWSGlEPTB;Nz62OVgzPiEQvF2= NUfy[JROW0GQR1XS
IA-LM NGTBbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvzTWM2OD15Lk[4OlE{KM7:TR?= MWDTRW5ITVJ?
SK-NEP-1 Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTdwNkm2NUDPxE1? NWrlcXlUW0GQR1XS
MDA-MB-415 NGG4bFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknjTWM2OD15Lki5NVg3KM7:TR?= NGTSRmtUSU6JRWK=
COLO-800 NWW0[VU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIizdldKSzVyPUeuPVQ1QTJizszN MXfTRW5ITVJ?
NCI-H2228 Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13wc2lEPTB;OD6xOVc5OyEQvF2= NGjrdm1USU6JRWK=
D-423MG MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qwT2lEPTB;OD6yNVczKM7:TR?= MXXTRW5ITVJ?
TE-1 NYHCSW5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfHTlNXUUN3ME24MlQ1OzF4IN88US=> NInyVYxUSU6JRWK=
NOS-1 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi2N|lKSzVyPUiuOVE2OzRizszN Mmj2V2FPT0WU
8505C NWr6eIl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rPPGlEPTB;OD62OFgzPCEQvF2= MmLkV2FPT0WU
HEC-1 NXe1SoRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;nV|ZKUUN3ME24Mlc5PDN7IN88US=> MWLTRW5ITVJ?
TE-11 NFi2V4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRThwOUm1OVEh|ryP MVvTRW5ITVJ?
CTB-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CyOWlEPTB;OT6wNVQ{OyEQvF2= NV[ycJNpW0GQR1XS
TGBC11TKB NHHCV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTlwMEKyOFEh|ryP NGDlRo1USU6JRWK=
NB17 NXvzWGxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTFTWM2OD17LkG4PFch|ryP MlLjV2FPT0WU
Becker MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHaPFlKSzVyPUmuOFE6PDRizszN MnrDV2FPT0WU
SN12C M3excGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnvTWM2OD17LkS1NlM1KM7:TR?= NID5c2JUSU6JRWK=
COLO-320-HSR MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTlwNkCyN|ch|ryP NUjS[|Y6W0GQR1XS
D-283MED MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm4NGpqUUN3ME25MlY{ODd{IN88US=> MWnTRW5ITVJ?
D-263MG M4qxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDsRXhKSzVyPUmuPFM{QDRizszN MXLTRW5ITVJ?
MEL-JUSO MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\hVnlZUUN3ME25MlkxOTJ5IN88US=> NFT1UXJUSU6JRWK=
T98G MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTlwOUCyNFMh|ryP MoPZV2FPT0WU
HLE M17BZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTlwOUC5NFkh|ryP MmT2V2FPT0WU
Ca9-22 MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDuXGlKSzVyPUGwMlA3PjVizszN M4\jZnNCVkeHUh?=
OS-RC-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFyLkGwOFUh|ryP MXTTRW5ITVJ?
T47D NHLFTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXoTWM2OD1zMD6xOVUh|ryP MUnTRW5ITVJ?
GI-1 NVXtZo5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFyLkO1N|Mh|ryP NIDuO4ZUSU6JRWK=
NUGC-3 M2fCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDjOVZMUUN3ME2xNE41PDB{IN88US=> NHjx[lJUSU6JRWK=
MDA-MB-361 NHexSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XxUWlEPTB;MUCuOFQ{OiEQvF2= MYDTRW5ITVJ?
SCC-15 NVzUfXFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFyLkS3NVgh|ryP NEDqNnVUSU6JRWK=
KS-1 NY\oZWVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z6cWlEPTB;MUCuOlMxOSEQvF2= MkDYV2FPT0WU
CAL-12T M1zNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXsfVRPUUN3ME2xNE43OzZzIN88US=> MoSyV2FPT0WU
OVCAR-4 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFyLkewOlgh|ryP MUXTRW5ITVJ?
HuP-T4 NUjwS4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPBOXBKSzVyPUGxMlA{OjhizszN MlHuV2FPT0WU
NCI-H358 NYXiNmJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP5V41KSzVyPUGxMlI3PTdizszN NYnTdm9tW0GQR1XS
HO-1-N-1 NEK5S|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjXU2ZVUUN3ME2xNU4{Ozl6IN88US=> MWXTRW5ITVJ?
NH-12 NIXZO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfrUJhTUUN3ME2xNU42Ozd6IN88US=> MWrTRW5ITVJ?
MOLT-4 NXTVUGZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX3PJhKSzVyPUGxMlU6QDVizszN M4m0eXNCVkeHUh?=
K-562 NYn0WYRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFzLkeyOFgh|ryP MWHTRW5ITVJ?
ES6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jG[mlEPTB;MUGuPFU5OSEQvF2= NIjJO4JUSU6JRWK=
RO82-W-1 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\wO2lEPTB;MUGuPVA3PCEQvF2= MkL1V2FPT0WU
Ramos-2G6-4C10 M{DxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFzLkmzNkDPxE1? NUPtUWp1W0GQR1XS
23132-87 NWTZVpJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HhOmlEPTB;MUKuNFgzOSEQvF2= MmK5V2FPT0WU
A549 NWTtb2V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4mxRmlEPTB;MUKuN|I5PSEQvF2= MkH4V2FPT0WU
NCI-H23 NFXadWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF{LkWwNlYh|ryP M3H6OXNCVkeHUh?=
H9 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonnTWM2OD1zMj61OVc4KM7:TR?= NX\LXnVzW0GQR1XS
LB771-HNC NIr1RldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr2OJdKSzVyPUGyMlc3PSEQvF2= M4C3WHNCVkeHUh?=
QIMR-WIL NIntbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnNTWM2OD1zMj64NlU5KM7:TR?= NXfSPWRZW0GQR1XS
HSC-3 M4HDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPL[G9DUUN3ME2xNk46Ojd4IN88US=> MYrTRW5ITVJ?
PFSK-1 M{DqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF{Lkm1NFch|ryP NWDIRlc2W0GQR1XS
ETK-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLzdYtSUUN3ME2xN{4xPzd7IN88US=> NInYfm5USU6JRWK=
SW1710 NXHLUYZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvTRWhmUUN3ME2xN{4{PjRzIN88US=> NUX1VZJ1W0GQR1XS
COLO-684 M2PMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn3boVkUUN3ME2xN{41PTRzIN88US=> Mo[wV2FPT0WU
RPMI-7951 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX4PZh{UUN3ME2xN{42OTN4IN88US=> NE\iUHpUSU6JRWK=
A101D NWD5cWI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojOTWM2OD1zMz61N|Q6KM7:TR?= M1PzOnNCVkeHUh?=
KE-37 NIDhflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i3N2lEPTB;MUOuOVg5PyEQvF2= M4C1[3NCVkeHUh?=
SiHa M3PFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqyT4EyUUN3ME2xN{45OzR4IN88US=> Mn74V2FPT0WU
NCI-H226 NIXB[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF|Lki4NFgh|ryP M3fE[XNCVkeHUh?=
DB M2fSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3XOVNVUUN3ME2xN{46QTJ6IN88US=> M{K3bHNCVkeHUh?=
HT-1197 NF\tWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7VTWM2OD1zND6wPFA6KM7:TR?= MnLvV2FPT0WU
SBC-5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHoSW5QUUN3ME2xOE4yOzZ{IN88US=> NX20XHhHW0GQR1XS
VMRC-RCZ M2XVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF2LkW3O|Qh|ryP MXfTRW5ITVJ?
697 M1rCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF2Lk[yO{DPxE1? MlL3V2FPT0WU
OMC-1 NX\DPGVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXDXYdKSzVyPUG0Mlc5QDhizszN MXjTRW5ITVJ?
SKG-IIIa MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXhd41KSzVyPUG0MlgxODFizszN NWewRod1W0GQR1XS
DOK NXjmeGhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr5eG1pUUN3ME2xOE46QTN|IN88US=> M1O2c3NCVkeHUh?=
NCI-H2029 NIHNNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF3LkO2NFIh|ryP NXvoRnRNW0GQR1XS
NCI-H2009 M37PSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF3LkWwPVUh|ryP NWTP[HdSW0GQR1XS
LK-2 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXvTWM2OD1zNT62OFQ6KM7:TR?= MXPTRW5ITVJ?
NCI-H661 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXBTWM2OD1zNT65NFc2KM7:TR?= NWrkXoY2W0GQR1XS
GT3TKB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF4LkC2O|Yh|ryP NF;CUZhUSU6JRWK=
GP5d Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF4LkO0NkDPxE1? Mk\sV2FPT0WU
SK-MEL-2 NVjxT29RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF4LkS0PFUh|ryP M1rrfnNCVkeHUh?=
SK-UT-1 NHraNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TMSWlEPTB;MU[uOVY2KM7:TR?= Ml7lV2FPT0WU
NB7 NI\2b5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{WwO2lEPTB;MU[uOlk4OSEQvF2= NX7vWHJLW0GQR1XS
NCI-H460 Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULFPGZjUUN3ME2xOk44OzJ4IN88US=> MYrTRW5ITVJ?
8305C NWTJ[21rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4faNGlEPTB;MU[uO|g4PyEQvF2= NHLGRpFUSU6JRWK=
CaR-1 M2fObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGyWmdvUUN3ME2xOk45OTFzIN88US=> M1u3fnNCVkeHUh?=
D-247MG MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLpTWM2OD1zNj64OlI2KM7:TR?= MVzTRW5ITVJ?
LoVo M3HqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rwbmlEPTB;MU[uPVQ5QCEQvF2= MX;TRW5ITVJ?
NCI-H2405 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH2[HU2UUN3ME2xO{4yQTB6IN88US=> MkfJV2FPT0WU
AU565 MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TWXWlEPTB;MUeuNlI2KM7:TR?= NFe5b4tUSU6JRWK=
OCI-AML2 NIfpNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\FNGJTUUN3ME2xO{42OzF5IN88US=> NEfOWXFUSU6JRWK=
22RV1 NV\rdoFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF5LkW4PFQh|ryP NUDRPIN1W0GQR1XS
HT-144 M1HLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLXTWM2OD1zNz62OVk5KM7:TR?= NGPuNWRUSU6JRWK=
HuO9 M3z2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XydWlEPTB;MUeuO|A{OSEQvF2= NFT6TXVUSU6JRWK=
Daoy MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnPOpN4UUN3ME2xO{44OTh2IN88US=> NILMTJJUSU6JRWK=
SJRH30 NVv0eW53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfqVGJKSzVyPUG3Mlg1QDlizszN MoXYV2FPT0WU
CHL-1 MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFK3dVNKSzVyPUG3MlkzPDlizszN M2O5THNCVkeHUh?=
J82 Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF5Lkm2N|Uh|ryP M1rkdXNCVkeHUh?=
COR-L23 NWTJPY5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHNTWM2OD1zOD6wNFEyKM7:TR?= MUDTRW5ITVJ?
SNU-C2B NFrEfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PEV2lEPTB;MUiuNlI4PiEQvF2= MmPvV2FPT0WU
NCI-H1770 NVP4T5dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zXRmlEPTB;MUiuOFYyPSEQvF2= NFPxe2VUSU6JRWK=
MHH-PREB-1 NWDaUnBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\1TWlEPTB;MUiuOVY6PyEQvF2= MVnTRW5ITVJ?
ES3 NWD3b2p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnLZlBzUUN3ME2xPE42QDh|IN88US=> M{T1enNCVkeHUh?=
MDA-MB-231 NFzKOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPHTWM2OD1zOD62OVAzKM7:TR?= MXPTRW5ITVJ?
MN-60 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXxXnFGUUN3ME2xPU4xPTl{IN88US=> Mn\ZV2FPT0WU
EPLC-272H NEW3NWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvVOWhKSzVyPUG5MlM4ODhizszN MVnTRW5ITVJ?
SW948 NIfpXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[5ZYhTUUN3ME2xPU4{QTN2IN88US=> NXnZ[GVCW0GQR1XS
MOLT-13 NWfHSo5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF7LkS1OFYh|ryP MX\TRW5ITVJ?
HL-60 M{XBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJyLkKxOFEh|ryP MYrTRW5ITVJ?
CP50-MEL-B M1\vcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJyLkS3OFgh|ryP NWXnNXdMW0GQR1XS
NTERA-S-cl-D1 NYPLVlkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJyLkS5O|gh|ryP NWT5c2NmW0GQR1XS
KINGS-1 MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vwV2lEPTB;MkCuO|k3PyEQvF2= MonqV2FPT0WU
DOHH-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jOWGlEPTB;MkCuPVA3KM7:TR?= NVrPe3pDW0GQR1XS
BB65-RCC M1XtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nxZ2lEPTB;MkCuPVI5PSEQvF2= NULPUlNoW0GQR1XS
NB12 NEPUTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K2cGlEPTB;MkGuNFM6PCEQvF2= MlLPV2FPT0WU
KY821 NGLrV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fIV2lEPTB;MkGuOVgzKM7:TR?= NXHnOFIxW0GQR1XS
PSN1 NWjjXnEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fnT2lEPTB;MkGuOlQ2OyEQvF2= M3LxNHNCVkeHUh?=
EGI-1 M1S1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTWZWNmUUN3ME2yNU44PDV2IN88US=> M33xSXNCVkeHUh?=
CTV-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TwbGlEPTB;MkKuN|A{OSEQvF2= MYLTRW5ITVJ?
TI-73 M2rWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ{LkO0PVgh|ryP MkHxV2FPT0WU
LCLC-103H NWSxU2xNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSxTWM2OD1{Mj60O|UzKM7:TR?= NFX0UGtUSU6JRWK=
D-542MG NVfhXlhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELPdY5KSzVyPUKyMlU2PThizszN M4TQb3NCVkeHUh?=
ATN-1 NGTPZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TQT2lEPTB;MkKuOlQ{QSEQvF2= MkjlV2FPT0WU
SK-MEL-1 NH7PPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi3ZYpKSzVyPUKyMlg{PjhizszN M1G4V3NCVkeHUh?=
HDLM-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\ncmlEPTB;MkOuNVQ4QCEQvF2= M4DQSHNCVkeHUh?=
UM-UC-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LlRWlEPTB;MkOuNVk1PCEQvF2= M2rDWnNCVkeHUh?=
NCI-H1573 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ|LkS2PFEh|ryP MXnTRW5ITVJ?
NCI-H520 M2K2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXkfItKSzVyPUKzMlQ6PDhizszN MYfTRW5ITVJ?
ESS-1 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HwRWlEPTB;MkOuPFA2QSEQvF2= M1HOSHNCVkeHUh?=
COR-L88 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHVOVBKSzVyPUKzMlk1PzVizszN MVHTRW5ITVJ?
TGBC24TKB NVrBZ4VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjjbYtKSzVyPUK0MlA{OTJizszN MWLTRW5ITVJ?
HCC1937 NWXoN3dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJ2LkGg{txO M3X2WHNCVkeHUh?=
RS4-11 M1vofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ2LkG0NkDPxE1? MVrTRW5ITVJ?
HCC38 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnJXFJkUUN3ME2yOE4zOzl2IN88US=> NULPfXU1W0GQR1XS
RPMI-2650 NWXDTId{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF70N49KSzVyPUK0MlYyPjJizszN MV\TRW5ITVJ?
P12-ICHIKAWA NVfON2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n5OWlEPTB;MkSuOlI2QCEQvF2= NHjyfoNUSU6JRWK=
YAPC NYXhNlhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2POUWlEPTB;MkSuPFIyPCEQvF2= MVjTRW5ITVJ?
NB13 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT2TWM2OD1{NT6yOlEyKM7:TR?= MmrvV2FPT0WU
SK-N-AS NEjxfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJ3Lki1PFQh|ryP M33W[HNCVkeHUh?=
SK-N-DZ NYPwVY45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDUTWM2OD1{Nj6wOFkh|ryP MnvqV2FPT0WU
LS-411N MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH1TWM2OD1{Nj6yNFM5KM7:TR?= MlfTV2FPT0WU
NCI-H810 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofoTWM2OD1{Nj6zNVEzKM7:TR?= NFLGeZhUSU6JRWK=
NCI-SNU-1 NF;nc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJ4LkW0OVQh|ryP MWDTRW5ITVJ?
HH NGLwe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX64VVdJUUN3ME2yOk42PTJ7IN88US=> NHT0SmlUSU6JRWK=
U-2-OS M{jDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\POmlEPTB;Mk[uO|M5OiEQvF2= NV3k[W9TW0GQR1XS
SF539 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7OTWM2OD1{Nj64NFE5KM7:TR?= NX7Z[JlkW0GQR1XS
NCI-H2052 Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPSTWM2OD1{Nz6wPFYh|ryP NUjQVFFlW0GQR1XS
A673 M4DJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFziSHBKSzVyPUK3MlIyODJizszN MX7TRW5ITVJ?
WM-115 M2rrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\0SGlEPTB;MkeuO|c3PyEQvF2= MmfoV2FPT0WU
SW48 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HXTGlEPTB;MkeuPFAxPSEQvF2= MUnTRW5ITVJ?
NOMO-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ5Lki1N|Ih|ryP NI\DT2FUSU6JRWK=
PC-3 NVnLW|BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHwNpNKSzVyPUK3Mlg6PDFizszN MoLoV2FPT0WU
UMC-11 NWXEPJpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJ5LkmzOFMh|ryP M1nHdHNCVkeHUh?=
U-118-MG M1XQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fsRWlEPTB;MkiuNFEzOyEQvF2= NXm3cWRvW0GQR1XS
NCI-H2452 M37BdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL0TWM2OD1{OD6wPFIzKM7:TR?= MmjRV2FPT0WU
CAMA-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnQRnVnUUN3ME2yPE45PTZ2IN88US=> NHXuTmdUSU6JRWK=
MC-IXC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzQTWM2OD1{OT6yN|Y3KM7:TR?= NXjkcppvW0GQR1XS
ES4 MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvIT5NJUUN3ME2yPU4{OTd{IN88US=> NEjT[WdUSU6JRWK=
BHT-101 NYDFSmtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrpbmtKSzVyPUK5MlMzOSEQvF2= MV\TRW5ITVJ?
KP-4 MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTYTWM2OD1{OT61NVYh|ryP NFLRVXVUSU6JRWK=
CAL-54 NFzLOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH6c2JKSzVyPUK5MlU1PDVizszN Mle3V2FPT0WU
5637 M1PlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF30Z4VKSzVyPUK5MlY1OjFizszN NIDSOYZUSU6JRWK=
MOLT-16 NUDXU5FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITyPGJKSzVyPUK5MlczPjlizszN NFnke5dUSU6JRWK=
Ca-Ski NVvZTmE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPTZ5hSUUN3ME2yPU46PDZizszN MYXTRW5ITVJ?
AsPC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTNyLkCyNVIh|ryP MY\TRW5ITVJ?
MSTO-211H NWLvOm85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknHTWM2OD1|MD6xOUDPxE1? NV3ke3FlW0GQR1XS
L-428 NYHM[mU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNyLkSwOUDPxE1? M1jCU3NCVkeHUh?=
SW1463 NH7iW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;vTWM2OD1|MD61N|g{KM7:TR?= NYXXWJh2W0GQR1XS
NCI-H1648 NYDwNpdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjSTWM2OD1|MD61OVc1KM7:TR?= NFfVO2FUSU6JRWK=
CAKI-1 NXLEbJVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNyLke3NFIh|ryP MUPTRW5ITVJ?
YKG-1 NUniN|VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXMNW01UUN3ME2zNU4xOjZ|IN88US=> NEPFc|JUSU6JRWK=
A2058 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonTTWM2OD1|MT6xNVY1KM7:TR?= NIrxe3FUSU6JRWK=
A375 NFvie3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\jS5JMUUN3ME2zNU4yPjl4IN88US=> MlHWV2FPT0WU
SNB75 MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ntO2lEPTB;M{GuNlQ{PSEQvF2= NI[wNm1USU6JRWK=
SK-HEP-1 M{DCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTNzLkSyO|Eh|ryP M3TKcHNCVkeHUh?=
ME-180 NE[zb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\TPGlEPTB;M{GuOlU1OiEQvF2= MmjXV2FPT0WU
NCI-H209 NH23e2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO2W4lKSzVyPUOxMlgzPDdizszN NIjGOm9USU6JRWK=
HC-1 NIHSNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPTSXU2UUN3ME2zNk4yPDR4IN88US=> NXvIcndvW0GQR1XS
LB373-MEL-D MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjhTWM2OD1|Mj6xPVcyKM7:TR?= M3X2XnNCVkeHUh?=
SNU-387 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfLUY9ZUUN3ME2zNk4{OTlzIN88US=> MVLTRW5ITVJ?
C32 NVuwNHhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTN{LkOzOVMh|ryP Mor6V2FPT0WU
EW-13 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;jNYJKSzVyPUOyMlk1ODhizszN MV\TRW5ITVJ?
BFTC-905 NVj5RVRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTXb2UzUUN3ME2zN{42OTN4IN88US=> NI\KZnVUSU6JRWK=
NCI-H1299 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L3WmlEPTB;M{OuOVYzOSEQvF2= M1PwPXNCVkeHUh?=
LU-135 M4PySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS5TWM2OD1|Mz64NFEh|ryP Mn:1V2FPT0WU
NCI-H2122 NV3IWGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD1RXdKSzVyPUOzMlk6PjZizszN NGfGOYRUSU6JRWK=
SK-LMS-1 NGLtbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G3[mlEPTB;M{SuOFExPyEQvF2= NEDDfHBUSU6JRWK=
LNCaP-Clone-FGC M1jYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XxdGlEPTB;M{SuPFUyPSEQvF2= M{TO[3NCVkeHUh?=
NCI-H1092 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTN3LkK3OFch|ryP MmD4V2FPT0WU
MS-1 NXjUUIxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\0SWlEPTB;M{WuN|A{QCEQvF2= MmjVV2FPT0WU
KYSE-510 NH;uco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\CRWZKSzVyPUO1MlUxPDJizszN NFHYO5JUSU6JRWK=
NCI-H1793 MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj0c5A{UUN3ME2zOU43PTR3IN88US=> MlLIV2FPT0WU
MIA-PaCa-2 NFjpfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfEZXBKSzVyPUO2MlA1QTZizszN MlzNV2FPT0WU
EW-22 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPmTWM2OD1|Nj60NFczKM7:TR?= Ml\aV2FPT0WU
IGR-1 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXiTWM2OD1|Nj64NVg1KM7:TR?= MoLrV2FPT0WU
HT-1080 NXX4SWZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HEU2lEPTB;M{euNVI2KM7:TR?= M36xNXNCVkeHUh?=
M14 NIX0U|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjqTWM2OD1|Nz6xOlQzKM7:TR?= MkfmV2FPT0WU
786-0 M4XTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M332UGlEPTB;M{euNlc6PCEQvF2= NVHNXYNHW0GQR1XS
MZ2-MEL M4G1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzUTWM2OD1|Nz60OVAyKM7:TR?= MYnTRW5ITVJ?
NCI-H510A NIPsVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTrb|NNUUN3ME2zO{46PDF{IN88US=> NX7N[IdLW0GQR1XS
LAN-6 M4HPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTN5Lkm1PFIh|ryP NXG3XXNJW0GQR1XS
SW620 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN6LkS5O|Qh|ryP NW\iUWdyW0GQR1XS
LB2241-RCC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\yVGlEPTB;M{muPFIxPSEQvF2= NF:1[WNUSU6JRWK=
Detroit562 NY\UW3dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTRyLkGyOlgh|ryP NULMSGR3W0GQR1XS
HN M2LNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrw[|lKSzVyPUSwMlE4QDJizszN M2rLTXNCVkeHUh?=
HCT-15 NHL2VYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjPTWM2OD12MD61PVA4KM7:TR?= M1u2UHNCVkeHUh?=
C2BBe1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrkPWpiUUN3ME20NE46OTV5IN88US=> NHvBdYlUSU6JRWK=
A498 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:yb2lEPTB;NEGuN|AyPSEQvF2= NEL2[IlUSU6JRWK=
SK-MEL-24 NFfhOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13yVGlEPTB;NEGuOFczPSEQvF2= NWjBUW1pW0GQR1XS
OVCAR-5 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRzLke3Olch|ryP MYTTRW5ITVJ?
NCI-H1792 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rqXGlEPTB;NEGuPVgzOSEQvF2= MXrTRW5ITVJ?
KOSC-2 M1rGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37Ge2lEPTB;NEKuNlY6QSEQvF2= NW\vZpE6W0GQR1XS
Mo-T NVG5TlByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXiXoVLUUN3ME20Nk45QTV6IN88US=> NGm0RlJUSU6JRWK=
CFPAC-1 NV\sNlVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rOeGlEPTB;NEOuOFk1PCEQvF2= NV3qNYxHW0GQR1XS
CAL-51 NVLaSoNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fVTWlEPTB;NEOuOVYxPSEQvF2= NV[zZpdCW0GQR1XS
RH-18 NVjXZZF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\RdGs5UUN3ME20N{45ODVizszN Ml;1V2FPT0WU
EC-GI-10 NIPMWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\JTWM2OD12Mz64N|Q4KM7:TR?= NEDUSm1USU6JRWK=
HSC-2 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnuSYZ7UUN3ME20OE4xODlizszN MorLV2FPT0WU
ML-2 MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS2TZl7UUN3ME20OU4zPjJzIN88US=> M1fseXNCVkeHUh?=
KNS-81-FD MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHNTWM2OD12NT63N|Y2KM7:TR?= NUeyT2lmW0GQR1XS
NB6 NGfpVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH0TWM2OD12Nj6xNVEh|ryP Ml3YV2FPT0WU
MCF7 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3OTWM2OD12Nj61OVM{KM7:TR?= MkDSV2FPT0WU
P30-OHK NUj6VIZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXMXFNjUUN3ME20Ok45OTF5IN88US=> MWDTRW5ITVJ?
BPH-1 NYPJeXZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:0dI95UUN3ME20Ok46QDB3IN88US=> MYfTRW5ITVJ?
U251 MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLnTWM2OD12Nj65PVQh|ryP MknGV2FPT0WU
MKN1 NWnZdHV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LvSGlEPTB;NEeuOVE{PyEQvF2= NU\0UnV7W0GQR1XS
A431 NIfLb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTR5LkizN|gh|ryP M2G4UHNCVkeHUh?=
C8166 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nFcmlEPTB;NEmuNlA{QSEQvF2= NH;0TpBUSU6JRWK=
HEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[weYxPUUN3ME20PU41ODZ2IN88US=> MnnSV2FPT0WU
RMG-I M37Gb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDZOVdKSzVyPUS5MlQ1PDRizszN NVribG1uW0GQR1XS
CAL-72 M4TOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HO[2lEPTB;NEmuOlA4PSEQvF2= MkjRV2FPT0WU
SW962 Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTR7LkmzN|Ih|ryP NXnQdYI{W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% CMC
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03595124 Recruiting Metastatic Renal Cell Carcinoma|Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|TFE3 Gene Translocation|TFEB Gene Translocation National Cancer Institute (NCI) October 9 2018 Phase 2
NCT03289533 Recruiting Carcinoma Hepatocellular Pfizer September 8 2017 Phase 1
NCT00828919 Active not recruiting Solid Tumors Pfizer March 7 2003 Not Applicable
NCT03297606 Recruiting Lymphoma Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors Canadian Cancer Trials Group|AstraZeneca|Bristol-Myers Squibb|Hoffmann-La Roche|Pfizer October 6 2017 Phase 2
NCT01210495 Completed Hepatocellular Carcinoma Pfizer December 6 2010 Phase 2
NCT03438708 Recruiting Clear Cell Renal Cell Carcinoma University of California San Diego|The Cleveland Clinic March 5 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products4

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID